- Conditions
- Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Interventions
- XL102, Fulvestrant, Abiraterone, Prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 149
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Meningioma
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Santa Monica, California + 14 more
- Conditions
- Cancer
- Interventions
- Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 59
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Lynwood, California + 46 more
- Conditions
- Advanced Metastatic Melanoma
- Interventions
- Cabozantinib, Pembrolizumab
- Drug
- Lead sponsor
- John Rieth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Colorectal Cancer
- Interventions
- Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo
- Drug · Biological
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 13
- States / cities
- Council Bluffs, Iowa • Grand Island, Nebraska • Omaha, Nebraska + 7 more
- Conditions
- Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
- Interventions
- XL228
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- XL092
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Interventions
- Angiogram, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Single Photon Emission Computed Tomography, Tremelimumab, Yttrium-90 Microsphere Radioembolization, Zanzalintinib
- Procedure · Biological · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Neoadjuvant Treatment, Thyroid Cancer
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Cleveland, Ohio • Houston, Texas + 1 more
- Conditions
- Metastatic Urothelial Carcinoma, Bladder Cancer
- Interventions
- Cabozantinib, Pembrolizumab
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Atlanta, Georgia • Salt Lake City, Utah
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
- Interventions
- cabozantinib
- Drug
- Lead sponsor
- Liza Villaruz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Colorectal Cancer
- Interventions
- Panitumumab, Cabozantinib
- Biological · Drug
- Lead sponsor
- John Strickler, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Interventions
- Cabozantinib, Atezolizumab
- Drug
- Lead sponsor
- Jun Zhang, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more
- Conditions
- Pancreatic Cancer
- Interventions
- Cabozantinib, Pembrolizumab
- Drug
- Lead sponsor
- Joseph Kim
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer, Rectal Cancer, Rectal Adenocarcinoma, Colorectal Cancer
- Interventions
- Cabozantinib, Nivolumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Belzutifan, Zanzalintinib, Cabozantinib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 904 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 10
- States / cities
- Anchorage, Alaska • Fullerton, California • Los Angeles, California + 6 more
- Conditions
- Metastatic Hormone Refractory Prostate Cancer
- Interventions
- Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection
- Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Renal Cell Carcinoma
- Interventions
- Cabozantinib, Nivolumab, Ipilimumab, Cabozantinib-matched placebo
- Drug · Biological
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 855 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 30
- States / cities
- La Jolla, California • Orange, California • Boca Raton, Florida + 23 more
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
- Interventions
- zanzalintinib, AB521, Nivolumab
- Drug · Biological
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Miami, Florida • Orlando, Florida + 11 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Cabozantinib, Sorafenib, Atezolizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 837 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 26 more
- Conditions
- Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma
- Interventions
- Zanzalintinib, Eribulin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2036
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Zanzalintinib, Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- Anwaar Saeed
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania • Houston, Texas • San Antonio, Texas
- Conditions
- Metastatic Renal Cell Carcinoma Treated With Cabozantinib
- Interventions
- Usability of an electronic symptom management application
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Durham, North Carolina • Raleigh, North Carolina
- Conditions
- Aggressive Variant Prostate Carcinoma
- Interventions
- Zanzalintinib
- Drug
- Lead sponsor
- Deepak Kilari
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin